Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection
Open Access
- 15 March 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (6) , 3531-3541
- https://doi.org/10.1128/jvi.77.6.3531-3541.2003
Abstract
Human papillomavirus type 16 (HPV16) is the primary etiologic agent of cervical carcinoma, whereas bovine papillomavirus type 1 (BPV1) causes benign fibropapillomas. However, the capsid proteins, L1 and L2, of these divergent papillomaviruses exhibit functional conservation. A peptide comprising residues 1 to 88 of BPV1 L2 binds to a variety of cell lines, but not to the monocyte-derived cell line D32, and blocks BPV1 infection of mouse C127 cells. Residues 13 to 31 of HPV16 L2 and BPV1 L2 residues 1 to 88 compete for binding to the cell surface, and their binding, unlike that of HPV16 L1/L2 virus-like particles, is unaffected by heparinase or trypsin pretreatment of HeLa cells. A fusion of HPV16 L2 peptide 13-31 and GFP binds (Kd, ∼1 nM) to ∼45,000 receptors per HeLa cell. Furthermore, mutation of L2 residues 18 and 19 or 21 and 22 significantly reduces both the ability of the HPV16 L2 13-31-GFP fusion protein to bind to SiHa cells and the infectivity of HPV16 pseudovirions. Antibody to BPV1 L2 peptides comprising residues 115 to 135 binds to intact BPV1 virions, but fails to neutralize at a 1:10 dilution. However, deletion of residues 91 to 129 from L2 abolishes the infectivity of BPV1, but not their binding to the cell surface. In summary, L2 residues 91 to 129 contain epitopes displayed on the virion surface and are required for infection, but not virion binding to the cell surface. Upon the binding of papillomavirus to the cell surface, residues 13 to 31 of L2 interact with a widely expressed, trypsin- and heparinase-resistant cell surface molecule and facilitate infection.Keywords
This publication has 82 references indexed in Scilit:
- Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid ProteinJournal of Virology, 2002
- Positively Charged Termini of the L2 Minor Capsid Protein Are Necessary for Papillomavirus InfectionJournal of Virology, 2001
- L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome EncapsidationJournal of Virology, 2001
- Human Papillomavirus Type 16 Minor Capsid Protein L2 N-Terminal Region Containing a Common Neutralization Epitope Binds to the Cell Surface and Enters the CytoplasmJournal of Virology, 2001
- Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 Å resolutionJournal of Molecular Biology, 1998
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopesJournal of General Virology, 1995
- Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachmentCell, 1993
- Synthesis and assembly of infectious bovine papillomavirus particles in vitroJournal of General Virology, 1993
- Mapping of linear epitopes of human papillomavirus type 16: The L1 and L2 open reading framesInternational Journal of Cancer, 1990